Valeant Builds Outside Of Dermatology With Bausch + Lomb Buy

Acquisition of Bausch + Lomb for $8.7 billion vaults Valeant Pharmaceuticals into consumer eye care and positions the firm to compete against pharma giants. Analysts see the move as representing “a good fit,” and the acquisition is not likely to be the last for Valeant, which has made M&A an integral part of its strategy.